ImmunityBio

US · IBRX #1397 by market cap Listed 1970

9.75 +0.06 +0.62%

Live - 5344 symbols - heartbeat 174s ago · 2026-10-08 07:00

Pre-market 9.72 -0.28%

After-hours 9.77 +0.16%

Overnight 9.70 -0.51%

Market cap: 10.33B
P/E (TTM): -10.26
P/B: -9.87
EPS: -0.38
Div yield: 0.00%
52W pos: 74%

Reader sentiment Are you bullish or bearish on IBRX?

Anonymous reader poll. Unscientific, not investment advice.

About ImmunityBio

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Founded: 2014
CEO: Mr. Richard Adcock
Employees: 691
Headquarters: San Diego, California, United States of America
Fiscal year end: 12-31
Website: immunitybio.com

Company profile

Exchange: US
Symbol: IBRX
Market-cap rank: #1397
Listing date: 1970-01-01
Market cap: 10.33B
Float cap: 3.97B
Shares out: 1.06B
Float shares: 406.69M

Sectors & themes

Biotechnology Top Gainers Yesterday Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 07:00:07 · For reference only, not investment advice and not tailored to your situation.